Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.55 |
| ▸ | ACHE | P22303 | 7/20 | 0.51 |
| ▸ | BACE1 | P56817 | 7/20 | 0.51 |
| ▸ | BCHE | P06276 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442445 | 0.86 | VCP (0.46) | HRH4LMNAKMT2AMEN1CYP1A2 | |
| SCHEMBL26348215 | 0.86 | VCP (0.46) | HRH4LMNAKMT2AMEN1CYP1A2 | |
| SCHEMBL26346156 | 0.86 | MEN1 (0.58) | HRH4ACHEBACE1BCHELMNA | |
| SCHEMBL26348272 | 0.83 | HRH4 (0.52) | HRH4ACHEBACE1BCHEPIK3CB | |
| SCHEMBL26348556 | 0.79 | HRH4 (0.55) | HRH4ACHEBACE1BCHELMNA | |
| SCHEMBL26348162 | 0.79 | MEN1 (0.58) | HRH4ACHEBACE1BCHELMNA | |
| SCHEMBL9310487 | 0.78 | ACHE (0.56) | ACHEBACE1BCHELMNAKMT2A | |
| SCHEMBL2804769 | 0.77 | CASP1 (0.59) | HRH4KMT2ACYP1A2CYP2D6MAPT | |
| SCHEMBL20692326 | 0.76 | HRH4 (0.56) | HRH4ACHEBACE1BCHELMNA | |
| SCHEMBL5153329 | 0.75 | LMNA (0.67) | HRH4LMNAKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MYB, MYBBP1A, MYCBP | HRH4 4801/4885ACHE 4510/4885BACE1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.